Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug Ozempic.) Eli Lilly is hot on Novo Nordisk's heels with its new obesity drug Zepbound.

(NYSE: PFE) remains on the outside looking in with this big opportunity. But that doesn't have to be the case. Should Pfizer acquire Viking Therapeutics (NASDAQ: VKTX) to take on Lilly and Novo Nordisk in the obesity-drug market?

Let's first look at the potential downsides to Pfizer acquiring Viking. One especially stands out: Pfizer already has two weight-loss candidates in its pipeline -- danuglipron and PF-07976016. The latter only recently advanced into clinical testing, so it has a long way to go. Danuglipron, though, is farther along in development.

Continue reading

Source Fool.com